Biomerica (NASDAQ:BMRA) Releases Earnings Results, Beats Expectations By $0.03 EPS

Biomerica (NASDAQ:BMRA) announced its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03, Fidelity Earnings reports. Biomerica had a negative return on equity of 61.29% and a negative net margin of 47.77%. The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.69 million.

Shares of BMRA traded up $0.14 during mid-day trading on Thursday, hitting $2.97. The stock had a trading volume of 351 shares, compared to its average volume of 21,362. The firm has a market cap of $29.36 million, a P/E ratio of -11.42 and a beta of 1.37. The business has a fifty day moving average price of $2.90 and a 200-day moving average price of $3.02. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.01 and a quick ratio of 1.39. Biomerica has a 52 week low of $2.06 and a 52 week high of $3.69.

BMRA has been the subject of several research analyst reports. ValuEngine lowered shares of Biomerica from a “hold” rating to a “sell” rating in a research note on Monday, December 30th. B. Riley set a $6.30 price objective on Biomerica and gave the company a “buy” rating in a research note on Monday, October 21st.

Biomerica Company Profile

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Featured Article: Why does a company issue an IPO?

Earnings History for Biomerica (NASDAQ:BMRA)

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.